News
11-16-2010, 07:10 AM
The U.S. Food and Drug Administration approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease. Breast cancer is the second leading cause of cancer related death among women, according to the National Cancer Institute...
More... (http://mnt.to/f/3MDz)
More... (http://mnt.to/f/3MDz)